Ken Drazan (file photo)

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

Back in late 2019, South San Fran­cis­co’s Ar­se­nal­Bio un­corked an $85 mil­lion round to kick­start its de­sign­er T cell project with some splashy back­ers on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.